查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1466040

移植HLA型檢測市場：依產品與服務、技術、移植類型、應用、最終用戶 - 2024-2030 年全球預測

HLA Typing for Transplant Market by Product & Service, Technology, Transplant Type, Application, End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年移植HLA型檢測市場規模為9.9831億美元，預計2030年將達18.3658億美元，複合年成長率為9.09%。

人類白血球抗原 (HLA) 分型是移植醫學中的重要過程，可辨識細胞表面上稱為 HLA 抗原的特定蛋白質。移植的HLA型檢測用於確認、匹配和監測器官、組織和幹細胞移植的供體和受體的兼容性。這個過程可以降低移植物排斥的風險並改善患者的整體治療效果，對於成功移植至關重要。此外，由於腎衰竭、肝硬化、心臟衰竭、糖尿病和血液疾病等慢性疾病的增加，對器官移植的需求不斷成長。精準醫學的進步將帶來基於個體基因組成的個人化方法，以提高捐贈者和接受者之間的兼容性。然而，進行此類測試需要更多訓練有素的專業人員，並且圍繞器官移植的同意政策存在倫理問題，使得人類白血球抗原（HLA）過程的執行更加困難。此外，次世代定序(NGS)、基於 PCR 的技術和Sanger定序等HLA型檢測方法的技術進步也有助於提高準確性並加快供體-受體匹配過程。政府透過促進器官捐贈和醫療基礎設施投資的宣傳宣傳活動提供支持，進一步支持市場擴張。

主要市場統計
基準年[2023] 9.9831億美元
預測年份 [2024] 1,086,390,000 美元
預測年份 [2030] 18.3658億美元
複合年成長率（%） 9.09%

技術採用分子檢測技術，具有高特異性和重現性

分子檢測技術因其高解析度、特異性和重現性而越來越多的採用。基於序列的分型 (SBT) 技術涉及對 HLA 基因的外顯子區域進行定序，以確定供體或患者樣本中存在的等位基因。該方法提供了盡可能高的解析度，並允許捐贈者和接受者的準確匹配。此外，聚合酵素鏈鎖反應(PCR) 方法涉及擴增目標 HLA 基因區域，然後進行探針雜合反應或限制性片段長度多態性 (RFLP) 分析，以鑑定特定的等位基因。非分子檢測技術包括透過血清學和細胞學方法HLA型檢測。這些主要用於低解析度打字足夠或由於成本或資源限制而無法使用分子方法時。血清學方法使用從先前分型的個體獲得的抗血清來測試血清樣本中是否存在特定的 HLA 抗原。細胞測定透過測量供體和受體免疫細胞在體外相互反應的能力來評估供體和受體免疫細胞的相容性。

產品和服務：優先考慮促進資料解釋和實驗室工作流程管理的軟體和服務

提供準確、高效的移植相容性測試結果的儀器在HLA型檢測過程中發揮關鍵作用。這包括定序儀、基於 PCR 的設備和其他測試設備。試劑和耗材是HLA型檢測過程的重要組成部分，因為它們確保測試結果的再現性、敏感度、特異性和可靠性。其中包括 DNA 擴增試劑、DNA序列測定試劑（基於 NGS）、探針雜合反應測定試劑套件、微陣列/固相測定以及實驗室使用的品管材料和標準品。軟體和服務對於HLA型檢測流程至關重要，因為它們有助於資料解釋、結果報告和實驗室工作流程管理。使用資料分析軟體、資料庫管理系統和能力驗證品質保證程序。

移植類型：幹細胞移植療法擴大用於治療白血病、淋巴瘤、骨髓瘤和免疫系統疾病。

器官移植以捐贈者的健康器官取代受損或無功能的器官。幹細胞移植治療方法多種血液相關疾病，包括白血病、淋巴瘤、骨髓瘤和免疫系統疾病。這涉及將健康的造血幹細胞移植到患者體內以替換受損或故障的細胞。幹細胞移植中的HLA型檢測對於確保供體和受體細胞的相容性並降低移植物抗宿主疾病 (GVHD) 的風險至關重要。組織移植涉及將健康的捐贈者組織（例如角膜、骨髓、血管或皮膚）移植到受體體內，以恢復器官功能或改善患者的生活品質。

HLA型檢測在應用器官移植診斷應用的應用

HLA型檢測適用於器官移植、造血幹細胞移植和輸血醫學的診斷應用，以確認捐贈者和受體之間的相容性。 HLA型檢測有助於識別相容器官，從而降低移植物排斥的風險並改善患者預後。 HLA型檢測廣泛應用於群體遺傳學、疾病相關研究、疫苗開發、藥物基因體學研究及精準醫學計畫等研究應用。此外， HLA型檢測提供了一種有效的工具來產生支持醫學進步的可靠資料。

最終用戶：尋求高通量能力和可擴展性的獨立參考實驗室的高普及率

醫院和移植中心構成了移植HLA型檢測分型的核心最終使用者部分。這些設施進行組織配對，以確定捐贈者和接受者之間的兼容性，確保器官和骨髓移植的成功。 HLA 為HLA型檢測服務提供快速週轉、高精度且經濟高效的解決方案。獨立參考實驗室在商業性向醫院和移植中心提供專門的診斷測試服務，例如HLA型檢測。這些實驗室因其高通量能力、擴充性和提高效率的技術進步而受到青睞。研究機構和學術機構利用次世代定序（NGS）、基於PCR的方法和HLA型檢測的Sanger定序等先進技術進行移植生物學科學研究。該部門主要尋求創新技術、易於使用的平台和廣泛的支援服務，以促進新調查方法的無縫實施。

區域洞察

由於技術進步和眾多器官移植手術的可用性，用於移植的人類白血球抗原 (HLA) 分型市場正在全球顯著成長。在美國和加拿大，由於器官移植需求的不斷成長， HLA型檢測的需求也不斷增加。美國國立衛生研究院 (NIH) 資助了多項研究舉措來改進HLA型檢測技術。此外，由於技術進步帶來更準確的HLA型檢測結果以及醫生和患者對器官移植的認知不斷提高，美洲的人類白血球抗原 (HLA) 分型市場預計將出現高速成長。在歐洲，由於人口老化導致需要器官移植的慢性疾病盛行率增加等因素，對HLA型檢測服務的需求正在穩步成長。此外，有利的報銷政策支持在歐洲接受移植手術的患者。沙烏地阿拉伯器官移植協會 (SSOT) 等組織致力於意識提升並加強國家之間的合作，例如波灣合作理事會(GCC) 器官移植計劃。由於遺傳病患病率高以及器官移植需求不斷成長，中國、日本和印度對HLA型檢測的需求不斷增加。中國國家自然科學基金委員會正在資助新的HLA型檢測技術的研究。此外，日本厚生勞動省也支持日本移植和細胞治療協會 (JSTCT) 等計劃。在印度，國家器官和組織移植組織 (NOTTO) 等政府措施透過提高公眾對器官捐贈的認知來促進市場成長。

FPNV定位矩陣

FPNV定位矩陣對於評估移植HLA型檢測市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可對可移植HLA型檢測市場中供應商的現況進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，以獲得市場競爭優勢。

本報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.移植用HLA型檢測市場的市場規模與預測是多少？

2.移植HLA型檢測市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些？

3.移植HLA型檢測市場的技術趨勢與法規結構如何？

4.移植HLA型檢測市場主要廠商的市場佔有率是多少？

5. 進入移植HLA型檢測市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 骨髓、器官和血液移植手術的發生率增加
      • 在個人化醫療中採用HLA型檢測來減少移植物排斥
    • 抑制因素
      • 缺乏承保範圍和保險不足
    • 機會
      • 移植診斷和HLA型檢測方法領域的技術進步
      • 優先考慮免疫抑制治療以補充HLA型檢測
    • 任務
      • 對HLA型檢測不準確的擔憂
  • 市場區隔分析
    • 技術：採用分子檢測技術，特異性高、重現性佳
    • 產品和服務：優先考慮促進資料解釋和實驗室工作流程管理的軟體和服務
    • 移植類型：越來越多使用幹細胞移植療法來治療白血病、淋巴瘤、骨髓瘤和免疫系統疾病
    • 應用： HLA型檢測在器官移植的診斷應用的應用
    • 最終用戶：獨立參考實驗室的高普及，可實現高通量能力和擴充性
  • 市場趨勢分析
    • 先進的醫療保健發展和成熟市場供應商的存在將促進HLA型檢測在美洲的擴展。
    • 移植HLA型檢測市場在亞太地區正在迅速擴大，我們致力於引進先進技術來改善移植醫療基礎設施。
    • 移植手術需求的不斷成長以及政府對高品質HLA型檢測商業化的支持為歐洲、中東和非洲地區創造了有利的市場條件
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析

第6章移植市場的HLA型檢測（依產品與服務）

  • 裝置
  • 試劑/耗材
  • 軟體和服務

第7章 移植HLA型檢測市場：依技術分類

  • 分子檢測技術
  • 非分子檢測技術

第8章 依移植類型分類的HLA型檢測市場

  • 器官移植
  • 幹細胞移植
  • 組織移植

第 9 章 移植HLA型檢測市場：依應用分類

  • 診斷應用
  • 調查申請

第 10 章 移植HLA型檢測市場：依最終使用者分類

  • 臨床實驗室/研究機構
  • 醫院及移植中心
  • 獨立參考實驗室

第11章 美洲HLA型檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太移植HLA型檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章 歐洲、中東和非洲移植HLA型檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • GenDx 推出 NGS-Turbo：利用 Oxford Nanopore Technologies 的定序設備徹底改變高解析度HLA型檢測
    • Omixon 推出單重人類白血球抗原擴增套件NanoTYPE MONO 和 MONOall RUO，與 Oxford Nanopore 的 MinION 平台相容。
    • JURA Bio 宣布與 Replay 產品公司 Syena 合作，推進癌症 T 細胞受體 NK 療法
    • Ossium Health 與 Be the Match 宣布合作，以提高骨髓移植的可近性和治療效率
    • BriaCell接受NCI津貼開發癌症平台
    • Tempus 宣布與 TScan Therapeutics伴同性診斷合作
    • Metropolis Healthcare 推出下一代 HLA 器官移植檢測
    • CD Genomics Longseq 部門宣佈人類白血球抗原 (HLA) 分型服務
    • Garuda Therapeutics 獲得 6,200 萬美元 B 輪資金籌措，以推進現成的血液幹細胞技術平台
    • FDA 已授予HLA型檢測測試 De Novo 分類，用作轉移性或不可切除的葡萄膜黑色素瘤 T 細胞受體治療的診斷輔助。
    • Eurobioscientific 以 1.323 億美元收購 GenDx
    • Be The Match BioTherapies 與 Atara Biotherapeutics 延長多年合作協議

第15章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-3D2FD205B873

[195 Pages Report] The HLA Typing for Transplant Market size was estimated at USD 998.31 million in 2023 and expected to reach USD 1,086.39 million in 2024, at a CAGR 9.09% to reach USD 1,836.58 million by 2030.

Human leukocyte antigen (HLA) typing is a vital process in medicine transplant that involves identifying specific proteins on the surface of cells, known as HLA antigens. The HLA typing for the transplant is used to identify, match, and monitor compatibility between donors and recipients for organ, tissue, or stem cell transplantation. This process is crucial to ensure a successful transplant by reducing the risk of graft rejection and improving overall patient outcomes. Moreover, the rising demand for organ transplants is due to an increase in chronic diseases such as kidney failure, liver cirrhosis, heart failure, diabetes mellitus, and hematological disorders. Precision medicine advancements can lead to personalized approaches based on individual genetic makeup for improved compatibility between donors and recipients. However, there is a need for more trained professionals performing these tests and ethical concerns surrounding organ transplantation consent policies, which restrict the growth of the Human leukocyte antigen (HLA) processes. Furthermore, technological advancements in HLA typing methods such as Next-Generation Sequencing (NGS), PCR-based techniques, and Sanger sequencing contribute to improved accuracy and a faster donor-recipient matching process. Government support through awareness campaigns promoting organ donation and investments in healthcare infrastructure further drive market expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 998.31 million
Estimated Year [2024] USD 1,086.39 million
Forecast Year [2030] USD 1,836.58 million
CAGR (%) 9.09%

Technology: Adoption of molecular assay technologies due to their high specificity and reproducibility

Molecular assay technologies are increasingly adopted due to their high resolution, specificity, and reproducibility. Sequence-based typing (SBT) techniques involve sequencing exon regions of HLA genes to determine the alleles present in a donor or patient sample. This method provides the highest resolution possible, allowing for precise matching between donors and recipients. In addition, Polymerase chain reaction (PCR) techniques rely on the amplification of target HLA gene regions followed by probe hybridization or restriction fragment length polymorphism (RFLP) analysis to identify specific alleles. Non-molecular assay technologies involve serological and cellular methods for HLA typing. They are primarily used when low-resolution typing is sufficient or where molecular methods may not be accessible due to cost or resource constraints. Serological techniques involve testing serum samples for the presence of specific HLA antigens using antisera obtained from previously typed individuals. Cellular assays assess the compatibility between donor and recipient immune cells by measuring their ability to respond to each other in-vitro.

Product & Service: Preference for software and services to facilitate data interpretation and managing laboratory workflow

Instruments play a crucial role in the HLA typing process as they provide accurate and efficient results for transplant compatibility testing. This includes sequencers, PCR-based instruments, and other laboratory equipment. Reagents and consumables are essential components of the HLA typing process as they ensure reproducibility, sensitivity, specificity, and reliability of test results. This constitutes DNA amplification reagents, DNA sequencing reagents (NGS-based), kits for probe hybridization assays, microarrays/solid-phase assays, and quality control materials & standards used in laboratories. Software and services are integral to the HLA typing process as they facilitate data interpretation, reporting of results, and laboratory workflow management. The software for data analysis, database management systems, and quality assurance programs for proficiency testing are used.

Transplant Type: Increasing use of stem cell transplantation therapy for leukemia, lymphoma, myeloma, and immune system diseases

Organ transplantation involves replacing a damaged or non-functional organ with a healthy one from a donor. HLA typing is essential in this process to minimize the risk of graft rejection due to immune system response, Stem cell transplantation is a therapy for various blood-related disorders such as leukemia, lymphoma, myeloma, and immune system diseases. It involves transplanting healthy hematopoietic stem cells into a patient to replace damaged or dysfunctional cells. HLA typing in stem cell transplantation is vital for ensuring the compatibility of donor and recipient cells, reducing the risk of graft-versus-host disease (GVHD). Tissue transplantation involves grafting healthy donor tissues such as corneas, bone marrow, blood vessels, and skin onto a recipient to restore the function of organs or improve the quality of patient's lives.

Application: Use of HLA typing in diagnostic applications for organ transplantation

HLA typing is preferred for diagnostic applications to ensure compatibility between donors and recipients for organ transplantation, hematopoietic stem cell transplantation, and transfusion medicine. It helps identify suitable matches to reduce the risk of graft rejection and improve patient outcomes. HLA typing is widely used in research applications for population genetics, disease association studies, vaccine development, pharmacogenomics research, and precision medicine initiatives. In addition, it provides efficient tools to generate robust data supporting advancements in medical science.

End-User: High penetration in independent reference laboratories for high-throughput capabilities and scalability

Hospitals and transplant centers form the core end-user segment for HLA typing for transplant purposes. These facilities perform tissue typing to determine compatibility between donors and recipients, ensuring successful organ or bone marrow transplants. HLA causes rapid turnaround time, high accuracy, and cost-effective solutions in HLA typing services. Independent reference laboratories provide specialized diagnostic testing services such as HLA typing to hospitals and transplant centers commercially. They are preferred due to high-throughput capabilities, scalability, and technological advancements that enhance efficiency. Research laboratories and academic institutes conduct scientific studies on transplantation biology using advanced techniques such as Next-Generation Sequencing (NGS), PCR-based methods, or Sanger sequencing for HLA typing. This segment primarily seeks innovative technologies, user-friendly platforms, and extensive support services to facilitate the seamless adoption of new methodologies.

Regional Insights

The Human leukocyte antigen (HLA) typing for transplant market is experiencing significant growth worldwide due to technological advancements and the availability of numerous organ transplant procedures. In the United States and Canada, demand for HLA typing is increasing due to growing organ transplantation needs. The National Institutes of Health (NIH) in the U.S. has funded numerous research initiatives to improve HLA typing techniques. Moreover, the Americas human leukocyte antigen (HLA) typing market is expected to grow at a higher rate due to increasing awareness about organ transplantation among both physicians and patients, along with technological advancements leading to more accurate HLA typing results. Europe has witnessed a steady increase in demand for HLA typing services owing to factors such as an aging population that increases the prevalence of chronic diseases requiring organ transplantation. Additionally, favorable reimbursement policies have supported patients undergoing transplant procedures in Europe. Organizations such as the Saudi Society for Organ Transplantation (SSOT) are working to increase awareness and collaborations between nations, such as the Gulf Cooperation Council (GCC) Organ Transplant Program. China, Japan, and India are witnessing an increased demand for HLA typing due to a high prevalence of genetic disorders and growing organ transplantation needs. China's National Natural Science Foundation has funded research on novel HLA typing techniques. Moreover, Japan's Ministry of Health, Labor, and Welfare supports projects such as the Japan Society for Transplantation and Cellular Therapy (JSTCT). In India, government initiatives, such as the 'National Organ and Tissue Transplant Organization (NOTTO) contribute to market growth by increasing public awareness about organ donation.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the HLA Typing for Transplant Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the HLA Typing for Transplant Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the HLA Typing for Transplant Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., BAG Diagnostics GmbH, Becton, Dickinson, and Company, BGI Genomics Co.,Ltd., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, CapitalBio Technology Co., Ltd., CareDx, Inc., CeGaT GmbH, Chugai Pharmaceutical Co., Ltd., Creative Biolabs, Inc., DiaSorin S.p.A., Eurofins Scientific SE, F. Hoffman-La Roche AG, Fujirebio, Inc. by H.U. Group Holdings, Inc., Garuda Therapeutics, GenDx by Eurobio Scientific Group, HEALIOS K.K., Hologic, Inc., Illumina, Inc., Immatics N.V., Immucor, Inc. by Werfen, S.A., ImmunOs Therapeutics AG, Invectys Inc., Laboratory Corporation of America Holdings, Lonza Group Ltd., Merck KGaA, NeoGenomics Laboratories, Inc., OraSure Technologies, Inc., Oxford Nanopore Technologies PLC, Pure MHC, LLC, Pure Protein, LLC, QIAGEN N.V., STEMCELL Technologies Inc., T-Cure Bioscience Inc., Takara Bio Inc., TBG Diagnostics Ltd., TCR2 Therapeutics by Adaptimmune Therapeutics PLC, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the HLA Typing for Transplant Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product & Service
    • Instruments
    • Reagents & Consumables
    • Software & Services
  • Technology
    • Molecular Assay Technologies
      • PCR-Based Molecular Assays
        • Real-Time PCR
        • Sequence-Specific Oligonucleotide-PCR
        • Sequence-Specific Primer-PCR
      • Sequencing-Based Molecular Assays
        • Next-Generation Sequencing
        • Sanger Sequencing
    • Non-Molecular Assay Technologies
  • Transplant Type
    • Organ Transplantation
    • Stem Cell Transplantation
    • Tissue Transplantation
  • Application
    • Diagnostic Applications
      • Antibody Screening
      • Chimerism Monitoring
    • Research Applications
  • End-User
    • Clinical Laboratories & Research Institution
    • Hospitals & Transplant Centers
    • Independent Reference Laboratories
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the HLA Typing for Transplant Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the HLA Typing for Transplant Market?

3. What are the technology trends and regulatory frameworks in the HLA Typing for Transplant Market?

4. What is the market share of the leading vendors in the HLA Typing for Transplant Market?

5. Which modes and strategic moves are suitable for entering the HLA Typing for Transplant Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of bone marrow, organ, and blood transplant processes
      • 5.1.1.2. Adoption of HLA typing in personalized medicine for reduced graft rejections
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of reimbursement and inadequate insurance policies
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in the field of transplant diagnostics and HLA-typing methods
      • 5.1.3.2. Preference for immunosuppressive therapies to complement HLA typing
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns regarding the inaccuracy of HLA typing
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Adoption of molecular assay technologies due to their high specificity and reproducibility
    • 5.2.2. Product & Service: Preference for software and services to facilitate data interpretation and managing laboratory workflow
    • 5.2.3. Transplant Type: Increasing use of stem cell transplantation therapy for leukemia, lymphoma, myeloma, and immune system diseases
    • 5.2.4. Application: Use of HLA typing in diagnostic applications for organ transplantation
    • 5.2.5. End-User: High penetration in independent reference laboratories for high-throughput capabilities and scalability
  • 5.3. Market Trend Analysis
    • 5.3.1. Advanced Healthcare R&D and presence of established market vendors facilitate the expansion of HLA typing in Americas
    • 5.3.2. Dynamically expanding HLA typing for transplant market in the APAC, with emphasis on advanced technology adoption for offering improved healthcare infrastructure for transplantation
    • 5.3.3. Rising need for transplant procedures and government support for commercializing quality HLA typing to create a favorable market landscape in EMEA
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. HLA Typing for Transplant Market, by Product & Service

  • 6.1. Introduction
  • 6.2. Instruments
  • 6.3. Reagents & Consumables
  • 6.4. Software & Services

7. HLA Typing for Transplant Market, by Technology

  • 7.1. Introduction
  • 7.2. Molecular Assay Technologies
  • 7.3. Non-Molecular Assay Technologies

8. HLA Typing for Transplant Market, by Transplant Type

  • 8.1. Introduction
  • 8.2. Organ Transplantation
  • 8.3. Stem Cell Transplantation
  • 8.4. Tissue Transplantation

9. HLA Typing for Transplant Market, by Application

  • 9.1. Introduction
  • 9.2. Diagnostic Applications
  • 9.3. Research Applications

10. HLA Typing for Transplant Market, by End-User

  • 10.1. Introduction
  • 10.2. Clinical Laboratories & Research Institution
  • 10.3. Hospitals & Transplant Centers
  • 10.4. Independent Reference Laboratories

11. Americas HLA Typing for Transplant Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific HLA Typing for Transplant Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa HLA Typing for Transplant Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. GenDx launches NGS-Turbo: revolutionizing high-resolution HLA typing with Oxford Nanopore Technologies sequencing devices
    • 14.3.2. Omixon Launches NanoTYPE MONO and MONOall RUO, a Singleplex Human Leukocyte Antigen Amplification kit compatible with Oxford Nanopore's MinION Platform
    • 14.3.3. JURA Bio Announces Partnership With Replay Product Company Syena to Advance T Cell Receptor NK Therapies in Cancer
    • 14.3.4. Ossium Health and Be The Match Unveil Partnership to Increase Bone Marrow Transplant Accessibility and Treatment Efficiency
    • 14.3.5. BriaCell receives NCI grant for cancer platform development
    • 14.3.6. Tempus Announces Companion Diagnostic Collaboration with TScan Therapeutics
    • 14.3.7. Metropolis Healthcare unveils NextGen HLA test for organ transplantation
    • 14.3.8. CD Genomics Longseq Division Unveils Human Leukocyte Antigen (HLA) Typing Service
    • 14.3.9. Garuda Therapeutics Secures USD 62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
    • 14.3.10. FDA Grants De Novo Classification to HLA Typing Test for Use as a Companion Diagnostic with a T Cell Receptor Therapy for Metastatic or Unresectable Uveal Melanoma
    • 14.3.11. Eurobio Scientific acquires GenDx for USD 132.3 million
    • 14.3.12. Be The Match BioTherapies, Atara Biotherapeutics Ink Multi-Year Partnership Extension

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. HLA TYPING FOR TRANSPLANT MARKET RESEARCH PROCESS
  • FIGURE 2. HLA TYPING FOR TRANSPLANT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. HLA TYPING FOR TRANSPLANT MARKET DYNAMICS
  • FIGURE 7. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. HLA TYPING FOR TRANSPLANT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. HLA TYPING FOR TRANSPLANT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HLA TYPING FOR TRANSPLANT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ORGAN TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ORGAN TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TISSUE TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TISSUE TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ANTIBODY SCREENING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ANTIBODY SCREENING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY CHIMERISM MONITORING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY CHIMERISM MONITORING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY CLINICAL LABORATORIES & RESEARCH INSTITUTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY CLINICAL LABORATORIES & RESEARCH INSTITUTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 67. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INDEPENDENT REFERENCE LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 68. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INDEPENDENT REFERENCE LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 79. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 82. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 83. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 84. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 85. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 86. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 87. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 88. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 91. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 92. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 93. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 94. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 95. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 96. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 97. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 98. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 99. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 100. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 101. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 102. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 103. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 104. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 105. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 106. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 107. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 108. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 109. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 110. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 111. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 112. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 113. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 114. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 115. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 116. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 117. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 120. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 121. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 122. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 123. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 124. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 125. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 126. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 127. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 128. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 129. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 130. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 131. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 132. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 133. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 134. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 135. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 138. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 139. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 140. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 141. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 142. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 143. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 144. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 145. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 146. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 147. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 148. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 149. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 150. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 151. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 152. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 153. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 156. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 157. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 158. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 159. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 160. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 161. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 162. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 163. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 164. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 165. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 166. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 167. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 168. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 169. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 170. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 171. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 174. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 175. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 176. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 177. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 178. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 179. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 180. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 201. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 202. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 203. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 204. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 205. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 206. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 207. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 208. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 209. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 210. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 211. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 216. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 217. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 218. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 219. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 220. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 221. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 222. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 223. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 224. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 225. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 226. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 227. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 228. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 229. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 232. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 233. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 234. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 235. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 236. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 237. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 238. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 239. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 240. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 241. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 242. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 243. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 244. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 245. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 246. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 247. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 250. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 251. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 252. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 253. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 254. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 255. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 256. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 257. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 258. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 259. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 260. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 261. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 262. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 263. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 264. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 265. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 268. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 269. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 270. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 271. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 272. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 273. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 274. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 275. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 276. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 277. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 278. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 279. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 280. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 281. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 282. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 283. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 284. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 285. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 286. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 287. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 288. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 289. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 290. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 291. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 292. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 293. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 294. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 295. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 296. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 297. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 298. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 299. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 300. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 301. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 302. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 303. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 304. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD